December 23, 2022
2 min watch
Save
VIDEO: CureSight platform shows promise in pediatric amblyopia treatment
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
CHICAGO — In this Healio Video Perspective from the AAO meeting, Burton J. Kushner, MD, discusses the positive impact the CureSight platform may have on pediatric amblyopia.
“The CureSight program is the only dichoptic treatment that has undergone a prospective randomized clinical trial comparing it to the standard of care, patching, and the results were that it was noninferior,” Kushner said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Kushner reports being on the scientific advisory board for NovaSight.
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.